Yoga-based gut aeration as an add-on therapy for H. pylori-linked APDs

Summaries 1 min 114

Font Size

Created On: 26/11/2025

Helicobacter pylori (H. pylori) infection stands as the leading trigger of acid-peptic diseases (APDs), marked by persistent acidity, reflux, and indigestion.

See All

Key take away

Yogic gut aeration techniques effectively ease gastrointestinal symptoms, reduce stress, and enhance quality of life in H. pylori-induced acid-peptic diseases.

Background

Helicobacter pylori (H. pylori) infection stands as the leading trigger of acid-peptic diseases (APDs), marked by persistent acidity, reflux, and indigestion. While proton pump inhibitors (PPIs) are the mainstay of therapy, their prolonged use fosters resistance, adverse effects, and economic strain. Given that H. pylori thrives in low-oxygen conditions, enhancing gut aeration offers a novel therapeutic avenue.

Yogic gut aeration techniques (YGATs), a precise fusion of controlled breathing and abdominal contractions, present a natural, drug-free approach to rebalance gut physiology. Researchers evaluated the therapeutic impact of YGATs on quality of life (QoL), gastrointestinal symptoms, and stress reduction in H. pylori-triggered APDs.

Method

In this randomized controlled trial, Patients with acidity, reflux, and epigastric pain were screened via endoscopy and rapid urease test (RUT) to confirm H. pylori infection. Overall, 34 RUT-positive patients were randomly assigned to two groups: the yoga group (n=16) practiced YGATs for 2 months and 7 days alongside standard PPI therapy, while the control group (n=18) received PPIs alone.

Gastrointestinal symptoms, stress, and QoL were examined via gastrointestinal symptom rating scale (GSRS), quality of life in reflux and dyspepsia (QOLRAD), and stress indicator questionnaire (SIQ). Data analysis was performed with split-plot ANOVA and Bonferroni-adjusted post hoc tests using IBM SPSS v24 to compare intra- and inter-group outcomes.

Result

The yoga group experienced a remarkable reduction in gastrointestinal symptoms and stress levels, along with a notable improvement in QoL, when compared to the control group.

Conclusion

The study showed YGAT as a safe, cost-effective adjunct for H. pylori-induced APDs, easing symptoms, reducing stress, and improving QoL. These findings support further clinical trials to confirm its therapeutic potential and broader healthcare benefits.